UY33807A - miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis - Google Patents

miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis

Info

Publication number
UY33807A
UY33807A UY0001033807A UY33807A UY33807A UY 33807 A UY33807 A UY 33807A UY 0001033807 A UY0001033807 A UY 0001033807A UY 33807 A UY33807 A UY 33807A UY 33807 A UY33807 A UY 33807A
Authority
UY
Uruguay
Prior art keywords
osteoarthritis
mirnas
indicators
diseases
tissue status
Prior art date
Application number
UY0001033807A
Other languages
English (en)
Inventor
Dr Kathrin Heermeier
Dr Thomas Leeuw
Dl Christiane Metz-Weidmann
Dr Joachim Saas
Dr Jochen Beninga
Dr Uwe Dietz
Dr Tilo Weiss
Dr Eckart Bartnik
Dr Hans Schneider
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33807A publication Critical patent/UY33807A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

La presente invención se refiere a microRNA (miRNA), en particular mir-22, como indicador de un estado del tejido o una enfermedad tal como artrosis (OA) y como molécula diana para el descubrimiento de una sustancia para el tratamiento de una artropatía. También se proveen métodos y compuestos para investigación, análisis y/o tratamiento de una artropatía, especialmente OA.
UY0001033807A 2010-12-17 2011-12-15 miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis UY33807A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306443 2010-12-17

Publications (1)

Publication Number Publication Date
UY33807A true UY33807A (es) 2012-07-31

Family

ID=45560875

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033807A UY33807A (es) 2010-12-17 2011-12-15 miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis

Country Status (4)

Country Link
AR (1) AR084332A1 (es)
TW (1) TW201238973A (es)
UY (1) UY33807A (es)
WO (1) WO2012080459A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017187426A1 (en) * 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
SG11202008921YA (en) * 2018-03-14 2020-10-29 Beth Israel Deaconess Medical Ct Inc Micro-rna and obesity
WO2019229489A1 (en) * 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mir-146a-5p and mir-186 as biomarkers of osteoarthritis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
DK0725788T3 (da) 1993-10-27 1999-08-23 Ribozyme Pharm Inc 2'-amido- og 2'-peptidomodificerede oligonukleotider
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
EP0889723B1 (de) 1996-03-25 2002-06-05 LTS LOHMANN Therapie-Systeme AG Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
WO1998037240A1 (en) 1997-02-24 1998-08-27 Tm Technologies, Inc. Anti-sense oligonucleotide pharmacological agents
AU2008232316A1 (en) * 2007-03-26 2008-10-02 Newcastle Innovation Limited Therapeutic targets and molecules
US20100202973A1 (en) * 2007-05-18 2010-08-12 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells

Also Published As

Publication number Publication date
TW201238973A (en) 2012-10-01
AR084332A1 (es) 2013-05-08
WO2012080459A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
ECSP13012572A (es) Análogos de nucleótidos sustituidos
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
EA201890915A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
CO6751275A2 (es) Triterpenoides c-17 y c-3 modificados con la actividad inhibidora de la maduración del virus de inmunodeficiencia humana
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
BR112015014987A2 (pt) Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular
EA201500426A1 (ru) Производные пирролотриазинона в качестве ингибиторов pi3k
ECSP13012448A (es) Nuevas aminopirazoloquinazolinas.
CO6990719A2 (es) Derivados de los nucleósidos sustituidos en 4´-azido, 3´-fluoro como inhibidores de la replicación del rna del vhc
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
ECSP11010816A (es) Nuevos Compuestos
ECSP13012613A (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
UY33807A (es) miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis